TRIO and neurodevelopmental disorder: For the GEFD1 mutants on which there have been functional studies, the majority show a reduction in TRIO-mediated activation of RAC1,17, 18, 19 but some also affect glutamatergic synaptic transmission, reinforcing the hypothesis that TRIO mutations are causative of these neurodevelopmental disorders.18